serval:BIB_D93B50365865
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy
10.1136/esmoopen-2016-000118
000408009400008
Manegold
Christian
author
Adjei
Alex
author
Bussolino
Federico
author
Cappuzzo
Federico
author
Crino
Lucio
author
Dziadziuszko
Rafal
author
Ettinger
David
author
Fennell
Dean
author
Kerr
Keith
author
Le Chevalier
Thierry
author
Leighl
Natasha
author
Papotti
Mauro
author
Paz-Ares
Luis
author
PĂ©rol
Maurice
author
Peters
Solange
author
Pirker
Robert
author
Quoix
Elisabeth
author
Reck
Martin
author
Smit
Egbert
author
Vokes
Everett
author
van Zandwijk
Nico
author
Zhou
Caicun
author
article
review
2017-01
ESMO Open
2059-7029
journal
1
6
e000118
Despite the efficacy of a number of first-line treatments, most patients with advanced-stage non-small cell lung cancer (NSCLC) experience disease progression that warrants further treatment. In this review, we examine the role of novel active agents for patients who progress after first-line therapy and who are not candidates for targeted therapies. More therapeutic options are needed for the management of patients with NSCLC after failure of first-line chemotherapy. A PubMed search was performed for articles from January 2012 to May 2015 using the keywords NSCLC, antiangiogenic, immunotherapy, second-line, novel therapies and English language articles only. Relevant papers were reviewed; papers outside that period were considered on a case-by-case basis. A search of oncology congresses was performed to identify relevant abstracts over this period. In recent years, antiangiogenic agents and immune checkpoint inhibitors have been added to our armamentarium to treat patients with advanced NSCLC who have progressed on first-line chemotherapy. These include nintedanib, a triple angiokinase inhibitor; ramucirumab, a vascular endothelial growth factor receptor-2 antibody; and nivolumab, pembrolizumab and atezolizumab, just three of a growing list of antibodies targeting the programmed death receptor-1 (PD-1)/PD ligand-1 pathway. Predictive and prognostic factors in NSCLC treatment will help to optimise treatment with these novel agents. The approval of new treatments for patients with NSCLC after the failure of first-line chemotherapy has increased options after a decade of few advances, and holds promise for future evolution of the management of NSCLC.
eng
60_published
true
peer-reviewed
University of Lausanne
mailto:serval_help@unil.ch
http://www.unil.ch/serval
http://serval.unil.ch/disclaimer
https://serval.unil.ch/notice/serval:BIB_D93B50365865